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Prior research has shown a relationship between early onset marijuana (MJ) use and
depression; however, this relationship is complex and poorly understood. Here, we utilized
passive music listening and fMRI to examine functional brain activation to a rewarding
stimulus in 75 participants [healthy controls (HC), patients with major depressive disorder
(MDD), frequent MJ users, and the combination of MDD and MJ (MDD + MJ)]. For each
participant, a preferred and neutral piece of instrumental music was determined (utilizing
ratings on a standardized scale), and each completed two 6-min fMRI scans of a passive
music listening task. Data underwent pre-processing and 61 participants were carried forward for analysis (17 HC, 15 MDD, 15 MJ, 14 MDD + MJ). Two statistical analyses were
performed using SPM8, an analysis of covariance with two factors (group × music type)
and a whole brain, multiple regression analysis incorporating two predictors of interest [MJ
use in past 28 days; and Beck Depression Inventory (BDI) score]. We identified a significant
group × music type interaction. Post hoc comparisons showed that the preferred music
had significantly greater activation in the MDD + MJ group in areas including the right middle and inferior frontal gyri extending into the claustrum and putamen and the anterior
cingulate. No significant differences were identified in MDD, MJ, or HC groups. Multiple
regression analysis showed that activation in medial frontal cortex was positively correlated with amount of MJ use, and activation in areas including the insula was negatively
correlated with BDI score. Results showed modulation in brain activation during passive
music listening specific to MDD, frequent MJ users. This supports the suggestion that
frequent MJ use, when combined with MDD, is associated with changes in neurocircuitry
involved in reward processing in ways that are absent with either frequent MJ use or MDD
alone. This could help inform clinical recommendations for youth with MDD.
Keywords: reward, cannabis, major depressive disorder, adolescent, young adult, mental health

INTRODUCTION
Survey, behavioral, translational, and brain imaging research has
found, to varying degrees, a relationship between marijuana (MJ)
use and mental illness. However, this relationship is complex and
poorly understood. Research shows that 20% of people with a
mental health issue have a co-occurring substance use problem,
often involving cannabis (1). Recreational MJ use is increasing
in prevalence in adolescence and now is even more pervasive than
cigarette smoking in youth (2). Additionally, a survey of 12th grade
students showed that the lifetime prevalence of MJ use was 36%
(3). Studies have shown that cannabis use can precipitate the onset
of mood disorders (and psychosis) in vulnerable youth (4), and a
growing body of research suggests an association between cannabis
use and the onset of mood disorders, especially in youth (5–8).
Thus, examining the relationship between MJ use and mental illnesses such as mood disorders is vital in order to mitigate risk to
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youth. This is especially important since the onset of most mood
disorders is before the age of 25 (9), which is when youth are most
likely to experiment with marijuana (2).
Due to the prevalence of common depressive symptoms in people who engage in frequent MJ use, such as anhedonia and lack of
motivation (10, 11), the neurocircuitry of reward processing may
be affected in both populations (10, 12, 13). A number of studies
have found abnormalities in the ventral striatum in both adults and
youth suffering from depression (14–18). Acute MJ use is associated with increased regional cerebral blood flow in areas known to
be involved in reward processing such as ventral and medial frontal
cortices, insula, anterior cingulate cortices, and a variety of subcortical regions (19–21). A meta-analysis of 43 studies of MJ use
showed a wide range of alterations in brain activation suggesting a
compensatory response to chronic cannabis exposure and abnormalities in prefrontal cortex (PFC), orbital frontal cortex, ventral
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striatum, thalamus, pons, and other reward-processing regions
(22). Chronic cannabis use has been shown to affect the brain’s
capacity for dopamine synthesis, an alteration related to schizophrenia and psychosis (23) and widely implicated in depressive
symptomatology (24, 25). Dopamine is one of the key neurotransmitters involved in reward processing (26), and alterations in this
neurotransmitter system during brain development, including the
adolescent years, may have longitudinal implications for the rest
of the individual’s life.
A variety of stimuli have been utilized in the investigation of
the neural circuitry underlying reward processing. Passive music
listening paradigms have been shown to strongly modulate activity in reward-related brain regions (27, 28) without involving a
cognitive processing component such as decision making. Both
MJ use and MDD have been shown to affect cognitive functioning
in youth (29, 30), and these deficits may lead to difficulty interpreting paradigms involving both cognitive processing and reward
processing. In this study, we utilized a passive music listening paradigm as a stimulus for reward processing without demand on
cognitive functioning, and fMRI to examine the neurocircuitry
of reward processing in late adolescents/young adult groups of
healthy controls (HC) and youth with major depressive disorder (MDD), frequent MJ use, and both MDD and frequent MJ
use. No previously published imaging work appears to have made
direct comparisons between reward-processing neurocircuitry in
MJ users, MDD, and the combination of MJ use with MDD. We
hypothesized that functional brain abnormalities associated with
MJ use alone and MDD alone would be exacerbated by their combination. The direct comparison of these groups is intended to help
uncover the complex interaction between MJ use and depression
and could illuminate combined risk for MJ use in the context of
MDD in youth. This information could provide preliminary evidence to help guide clinical recommendations related to marijuana
use in youth with MDD. This is an increasingly important topic as
more regions in North America consider legalizing marijuana.

MATERIALS AND METHODS
PARTICIPANTS

Approval for the protocol was obtained from the research ethics
board at Western Ontario, London, Ontario, Canada. After a complete description of the study to the participants, written informed
consent was obtained. Participants were recruited from the local
community and through the First Episode Mood and Anxiety
Program (FEMAP) in London, Ontario, Canada.
Data were collected from a total of 75 participants. These
included 20 HC, 17 youth with MDD, 20 youth with frequent
MJ use, and 18 youth with frequent marijuana use and either
active or recent major depressive disorder (MDD + MJ). Group
assignments were based on the psychiatric diagnosis made by the
treating psychiatrist, confirmed by the Structured Clinical Interview for Diagnosis, DSM-IV. Frequent MJ use was assessed by
self-report and confirmed by urine screen. Previous research has
stratified MJ users in numerous different ways (29, 31). “Frequent”
use in this study was defined to be ≥ 4 times per week for at least
3 months preceding the study. The category of “non MJ users”
allowed for minimal MJ use since the elimination of any lifetime MJ use was prohibitively restrictive and would decrease the
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comparability among groups on other variables. Non-significant
use was defined as ≤4 times per month for the past year. These
limits were chosen to differentiate clinically less serious adolescent/young adult “experimentation,” in the controls, from more
consistent MJ use (using the drug more days that not) in the designated MJ users. However, these specifications did not account for
the quantity of MJ used on any given day it was used. To confirm
group assignments, those participants in the MJ and MJ + MDD
groups had positive urine screens for MJ use, and those in the HC
and MDD groups had negative urine screens for MJ use.
Prior to fMRI data acquisition, participants were administered the Structured Clinical Interview for DSM Disorders
(SCID-I), SCID-II Personality Questionnaire, Family History
Screen – Subject Version, Hamilton Depression Rating Scale 21item (HDRS), Bryden Handedness Questionnaire, Adult ADHD
Self-Report Scale (ASRS-v1.1), the Snaith-Hamilton Pleasure
Scale (SHPS), Trauma History Questionnaire (THQ), Youth
Risk Behavior Surveillance System Questionnaire (YRBS), Emotion Regulation Questionnaire (ERQ), Socioeconomic Status and
Demographic Questionnaire, Weschler’s Abbreviated Scale of
Intelligence (WASI), Weschler’s Memory Scale (WMS-III), Auditory Processing Composite (APC), and Delis–Kaplan Executive
Function System [D-KEFS (DK)]. On the day of the scan, the
Spielberger state anxiety inventory (STAI) and the Beck Depression Inventory (BDI)-II were administered to account for mood
state on scan day. Because of the high co-use of MJ, alcohol, and
tobacco, the use of both alcohol and tobacco was also recorded.
The Timeline Follow Back was administered on scan day to evaluate the previous 28 days of MJ and alcohol use. Tobacco use in the
last month was recorded in the YRBS.
Participants had no history of head injury or serious medical illness (other than psychiatric diagnosis). The participants included
in the MDD group met current criteria for a major depressive
episode, while those in the MDD + MJ groups met diagnostic criteria for either current or past MDD, and a total of 13 participants
were taking psychoactive medications (primarily SSRIs). There
were no significant differences in antidepressant use between the
MDD and MDD + MJ groups (p = 0.09, n.s.). The doses of medication were stable for 3 weeks prior to fMRI data acquisition. The
participants included in the HC group had no history of antidepressant use or personal or family history of psychiatric illness as
determined by the SCID. No participants in the MJ group met
criteria for a current or past depressive episode. Participants were
not excluded based on alcohol use.
PROCEDURE

All magnetic resonance imaging (MRI) was performed using a
3.0 T MRI scanner (Siemens Verio, Erlangen, Germany) at the
Lawson Health Research Institute, using a 32-channel phased
array head coil (Siemens). Whole-brain T1-weighted anatomical images with 1mm isotropic spatial resolution were acquired
and used as reference for spatial normalization of the data, and
to select the orientation of functional MRI images 6° coronal to
the AC–PC plane. Music was presented during functional image
acquisition (SereneSound audio system and headset). Functional
MRI scans consisted of a single-shot echo-planar (T2*-weighted)
pulse sequence (volume acquisition time 3 s; 60 slices; 2 mm thick;
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voxels size 2 mm3 isotropic, FOV 25.6 cm × 25.6 cm) for a total
time of 6 min per series (two automatically discarded steady-state
volumes and 114 brain volumes). Two series were acquired for a
total of 228 functional volumes collected for each participant.
Music listening paradigm

For each participant, a preferred and neutral piece of instrumental music was determined utilizing ratings on a standardized scale.
Prior to scanning, participants were asked to bring in a selection of their own preferred instrumental music, and the preferred
music for each participant was selected from these options. This
methodology has been utilized in our previous study (27). A bank
of neutral music was built from the preferred selections of participants such that a piece of music assessed to be preferred by
one participant was a choice of neutral music for the other participants. The earliest participants could choose from a bank of
preferred music identified in our prior study using this paradigm
in a similar aged participant population (27).
Before scanning, participants listened to both their preferred
and neutral music to ensure their subjective experience of them
was appropriate for each category. This also familiarized participants to the neutral music to reduce novelty effects. For each piece
of music, participants were asked: (1) how much did you like the
neutral/preferred music you just heard on a scale from 0 to 100;
(2) how much would you like to hear this neutral/preferred music
again on a scale from 0 to 100; and (3) to rate the neutral/preferred
music you just heard on a scale from −100 to +100.
Each 6-min functional MRI scan consisted of alternating
90-s blocks of music (either preferred or neutral), followed by
60-s blocks of rest (silence). Participants heard two blocks of
music (one preferred and one neutral) in each of the two functional scans. The order of the music presentation was randomized
across participants. Immediately after fMRI data acquisition, but
while still in the MRI machine, subjective enjoyment of the passive music listening was assessed by asking participants to rate each
of the music stimuli, using the same standardized scale described
above.
DATA ANALYSIS

All fMRI data underwent pre-processing including motion correction (INRIAlign), spatial normalization into the standard Montreal Neurological Institute space, and spatial smoothing with a 3D
Gaussian kernel with a 8 mm full width at half-maximum radius in
preparation for statistical analysis (SPM8, http://www.fil.ion.ucl.
ac.uk/spm). In addition, Artifact Detection Tools (ART) software
was utilized and those participants with 5 or greater identified artifacts were excluded, carrying forward 61 participants for further
analysis. The small number of artifacts remaining was primarily
movement related. This was addressed by utilizing six realignment parameters calculated during pre-processing and entered as
regressors of no interest during statistical analysis to remove residual motion artifacts. Remaining were 17 HC, 15 MDD, 15 MJ,
and 14 MDD + MJ participants. In the MDD + MJ group, 10 met
current criteria for current MDD and 4 for past MDD. All statistical analyses were performed using SPM8. Individual participant
SPM contrast maps were calculated using the general linear model
framework. For each participant, the first 45 s of each music block
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was modeled using a standard boxcar design convolved with a
canonical hemodynamic response function. The first 45 s was used
to capture the peak activation related to the task that we hypothesized was most reflective of the reward component of the preferred
music. Each music condition block was then compared to the
rest condition. These participant-specific maps were then carried
forward into a whole brain, second level (between participants;
random effects) analysis of covariance (ANCOVA) with two factors involving four groups (HC, MDD, MJ, MDD + MJ) and two
music types (preferred, neutral). Sex was included in our model as
a regressor of no interest to account for differences in sex composition between groups. Correction for multiple comparisons are
as indicated below for each analysis.
Additionally, we performed a whole brain, multiple regression
analysis, which incorporated two predictors of interest, MJ use
during the past 28 days, and score on the BDI, to examine the
relationship between task-related activation and scores on these
measures.

RESULTS
QUESTIONNAIRES

Table 1 shows demographic and clinical variables for all participants for whom individual test scores were available (degrees of
freedom listed), separated by participant group. There were significant differences between groups in sex composition, with more
males than females in both MJ subgroups, but no significant differences existed in age among groups. For age of first MJ use, 13
HC participants and 6 MDD participants had never used MJ, while
conversely, 8 MJ participants (4 missing data) and 13 MDD + MJ
participants had started using MJ before the age of 17. There were
significant differences across groups (Pearson Chi-square = 34.8,
df = 9, p < 0.0005). With regard to alcohol use, 4 participants had
never used alcohol (2 HC and 2 MDD). The mode for age of onset
of alcohol use in the HC group was equal between age 15–16 and
over 17; the mode for MDD participants was age 17 or over, while
for both the MJ (2 missing data) and MDD + MJ participants, it
was 13–14 (n.s.).
Interestingly, tobacco use in the last month and MJ use in
the last month were correlated only in the non-marijuana users
(Spearman’s r = 0.46, p = 0.008, two-tailed, N = 32), perhaps due,
in part, to the lack of range in marijuana ratings. Marijuana
smokers in both depressed and non-depressed youth showed no
correlations among MJ, alcohol, or tobacco use in the last month.
In Table 1, an ANCOVA shows group differences in participant responses to the questionnaires using sex as a covariate of
non-interest. Significant group differences were present for variables such as the BDI, HDRS, SHPS, and rates of recent MJ use,
as expected. Significant differences among groups on a number of
other measures were also present. The MDD + MJ group scored
higher on lifetime trauma exposure than either of the two nonmarijuana using groups. The two depressed groups scored higher
than the two non-depressed groups for anxiety. The non-depressed
groups had lower suppression scores on emotion regulation indicating less maladaptive coping than the two depressed groups
while the HC had higher reappraisal scores than MDD, and MJ
had higher reappraisal scores than MDD + MJ, indicating better adaptive coping. There were no significant differences on the
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Table 1 | Demographic and clinical variables.
Count or mean (SD)
HC

MDD

MJ

MDD + MJ

(n = 17)

(n = 15)

(n = 15)

(n = 14)

a

b

c

d

Statistic

p-Value

χ2 [3, 61] = 13.56

0.004

F [3,57] = 0.18

0.911

DEMOGRAPHICS
Gender
Male
Female

Father

2

10

10

13

5

4

20.0 (1.1)

Age at scan (SD)
Mother

6
11

educationa

19.7 (2.1)

5.4

educationa

20.2 (1.3)

5.6

5.4

5.5

5.5

5.7

19.9 (1.7)
5.7

χ2 [15,

52] = 12.78

0.620

5.1

χ2 [18,

52] = 13.58

0.756

CLINICAL VARIABLES, MEAN (SD)
Depression (Bonferroni corrected threshold p < 0.017 )
BDI

2.6 (3.5)

27.9 (8.9)

7.0 (7.6)

23.1 (14.3)

F [3,57] = 26.69

<0.001 (a ↔ b,d; b ↔ c, c ↔ d)

HDRS

0.4 (0.7)

14.0 (3.4)

2.2 (3.9)

13.5 (9.2)

F [3,56] = 28.73

<0.001 (a ↔ b,d; b ↔ c, c ↔ d)

SHPS

20.8 (6.4)

31.7 (5.4)

21.7 (3.0)

29.8 (6.6)

F [3,57] = 17.04

<0.001 (a ↔ b,d; b ↔ c, c ↔ d)

Substance use (Bonferroni corrected threshold p < 0.01)
Lifetime MJ useb
MJ use past month
Lifetime alcohol useb
Alcohol use past month
Tobacco use past month

(days)c

1.8 (1.6)

2.4 (1.5)

6.8 (0.4)

6.9 (0.4)

F [3,54] = 60.87

<0.001 (a,b ↔ c; a,b ↔ d)

0 (0)

0.2 (0.8)

22.0 (6.2)

20.5 (9.2)

F [3,57] = 68.95

< 0.001 (a,b ↔ c; a,b ↔ d)

5.0 (1.8)

3.8 (2.0)

6.6 (0.8)

6.1 (0.8)

F [3,55] = 5.47

0.002 (b ↔ c,d)

14.5 (19.6)

5.1 (9.5)

34.5 (27.0)

25.6 (54.4)

F [3,57] = 1.08

0.367

1.1 (0.5)

1.2 (0.4)

2.5 (2.0)

2.9 (2.2)

F [3,55] = 4.83

0.005 (a,b ↔ d)

Other (Bonferroni corrected threshold p < 0.01)
Adult ADHD self-report – scale A

1.4 (1.5)

2.9 (1.7)

2.4 (1.5)

2.9 (1.9)

F [3,55] = 3.05

0.036

Trauma history questionnaire

1.8 (1.4)

1.7 (1.7)

2.9 (2.9)

4.8 (4.5)

F [3,55] = 4.29

0.009 (a,b ↔ d)

Speilberger state anxiety scale

30.2 (8.4)

48.7 (12.0)

35.0 (10.5)

47.9 (11.5)

F [3,56] = 11.63

<0.001 (a ↔ b; b ↔ c; a,c ↔ d)

Emotion regulation reappraisal

31.5 (5.1)

25.4 (5.1)

30.1 (7.4)

24.3 (8.1)

F [3,57] = 5.10

0.003 ( a↔ b; c ↔ d)

9.5 (3.3)

12.4 (3.4)

8.6 (4.5)

13.1 (3.5)

F [3,57] = 6.80

0.001 (a ↔ b; b ↔ c; c ↔ d)

111.2 (10.8)

110.1 (10.3)

105.2 (15.6)

104.6 (6.3)

F [3,57] = 1.36

0.264

Emotion regulation suppression
COGNITION, MEAN (SD)
Weschler abbreviated scale of
intelligence (WASI)

Weschler memory scale III (Bonferroni corrected threshold p < 0.007 )
General memory

55.1 (5.9)

55.5 (8.3)

51.0 (8.5)

49.6 (8.5)

F [3,57] = 0.86

0.466

Working memory

22.2 (5.4)

19.8 (4.8)

21.7 (3.8)

21.9 (2.7)

F [3,57] = 0.68

0.568

Immediate memory

43.6 (5.8)

41.9 (6.8)

39.4 (7.5)

37.9 (7.0)

F [3,57] = 1.33

0.273

52.6 (31.7)

59.0 (29.3)

51.3 (28.9)

46.2 (30.1)

F [3,57] = 0.17

0.917

53.8 (29.8)

44.0 (27.5)

44.8 (20.9)

41.4 (23.7)

F [3,57] = 0.64

0.590

48.8 (24.2)

53.2 (27.7)

40.4 (20.8)

50.0 (30.3)

F [3,57] = 0.40

0.753

Single trial
Learning percentile
Learning slope
percentile
Retrieval
percentile

(Continued)
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Table 1 | Continued
Count or mean (SD)
HC

MDD

MJ

MDD + MJ

(n = 17)

(n = 15)

(n = 15)

(n = 14)

a

b

c

d

Statistic

p-Value

F [3,57] = 1.44

0.239

Retention
percentile

66.3 (21.1)

74.3 (20.3)

65.5 (22.6)

54.6 (33.4)

Delis-Kaplan executive functioning system, mean (SD) (Bonferroni corrected threshold p < 0.017 )
Letter fluency
Total correct

13.3 (3.6)

10.5 (3.1)

13.3 (4.0)

14.2 (3.6)

F [3,57] = 1.87

0.144

14.5 (4.1)

12.5 (3.7)

14.1 (3.4)

13.6 (4.0)

F [3,57] = 0.74

0.534

13.6 (4.5)

13.1 (2.9)

13.6 (2.4)

12.0 (3.4)

F [3,57] = 0.60

0.617

Category fluency
Total correct
Category switching
Total correct

HC, healthy controls; MDD, major depressive disorder; MJ, marijuana; MDD + MJ, depression and marijuana users; BDI, beck depression inventory; HDRS, Hamilton
Depression Rating Scale; SHPS, Snaith-Hamilton Pleasure Scale.
a

1 = less than grade 7, 2 = grade 9, 3 = part of high school (grade 10/11), 4 = high school grad, 5 = part college or specialized training, 6 = college/university grad,

7 = graduate professional training (graduate degree).
↔ indicates a statistical difference between variables in columns (a,b,c,d) on either side of symbol.
YRBS (1 = never, 2 = 1–2 times, 3 = 3–9, 4 = 10–19, 5 = 20–39, 6 = 40–99, 7 = > 100).

b
c

YRBS (1 = never, 2 = 1–2 days, 3 = 3–5, 4 = 6–9, 5 = 10–19, 6 = 20–29, 7 = all 30 days).

ADHD measure across groups. Likewise, there were no differences
on any of the cognitive measures across groups.
MUSIC RATINGS

An ANOVA with two factors, group (HC, MDD, MJ, MJ + MDD)
and music type (neutral, preferred), found no significant difference in music ratings between groups (F = 0.87; p < 0.52).
ANCOVA

An ANCOVA (SPM8, http://www.fil.ion.ucl.ac.uk/spm) was performed (n = 61) to examine differences among HC, MDD, MJ,
and MDD + MJ groups in the passive music listening task. We
identified no main effect of group or music type. However, a
significant group × music type interaction was present (F = 8.42;
p < 0.05; FDR) as shown in Figure 1A with beta weights illustrated
in Figure 1B and regions identified in Table 2. Figure 2 shows the
results of post hoc comparisons indicating significant differences
between preferred and neutral music in the MDD + MJ group,
with the preferred music having significantly greater activation
(T = 3.8; p < 0.05; FDR-cluster) in a number of areas including
the right middle frontal gyrus, right claustrum (extending into the
putamen), and dorsal anterior cingulate (see Table 2). We performed all possible post hoc comparisons and no other significant
differences were identified within the MDD, MJ, or HC groups or
between the groups.
MULTIPLE REGRESSION

Figure 3 and Table 2 show the results of a multiple regression
analysis examining task-related music listening activation (preferred music) in the MDD + MJ group and individual participant
scores on MJ use (total MJ used during the past 28 days) and
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depression rating on the day of the scan (BDI). Figure 3A shows
voxels with a significant positive correlation with MJ use (T = 4.74;
p < 0.01; FDR-cluster). These voxels are primarily located in
regions localized to the medial frontal cortex, extending from the
medial orbital gyrus (BA 11) and the ventral anterior cingulate
cortex (ACC) (BA 24) to the dorsal ACC (BA 32), and including
the subgenual ACC (BA 25) (described in Table 2). No voxels were
identified that showed a significant negative correlation with MJ
use. Figure 3A also shows a scatter plot indicating the relationship between individual participant beta weights of the identified
voxels and the number of times they used MJ in the past 28 days.
Figure 3B shows voxels with a significant negative correlation to
scores on the BDI (T = 4.53; p < 0.01; FDR-cluster). These voxels
are located in the insula, extending into the precentral gyrus (BA 4)
and the postcentral gyrus (BA 3), described in Table 2. No voxels
were identified that showed a significant positive correlation with
scores on the BDI. Figure 3B right panel shows a scatter plot indicating the relationship between individual participant beta weights
of the identified voxels and scores on the BDI.

DISCUSSION
The present study used a passive music listening paradigm to
examine reward-processing differences in fMRI activation among
four groups of youth: HC, frequent MJ users, youth with MDD,
and frequent MJ users with MDD. There were several significant
group differences including sex, anxiety, emotion regulation style,
trauma history, lifetime alcohol use, and past 30 day tobacco use,
in addition to the expected differences in depression symptoms
and MJ use. Regarding anxiety, the two depression groups had
similarly high scores, and likewise, for emotion regulation style, it
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FIGURE 1 | ANCOVA group × music interaction. (A) shows clusters of
activated voxels in the sagittal, coronal, and transverse perspectives overlaid
on a normalized T1-weighted anatomical image at MNI planes indicated.

was the two depression groups that stood out as the most maladaptive compared to the HC and MJ groups. There were no
significant group differences in alcohol use in the past month, but
the MDD group had less lifetime alcohol use than the MJ or the
MDD + MJ groups. In addition, the MDD and MDD + MJ groups
included youth taking medication for depression and though medications did not differ between these groups, the HC and MJ
alone groups were medication free. All groups reported similarly positive ratings to their preferred music and similarly neutral
ratings to the “neutral” music that they heard during fMRI data
aquisition.
We identified a significant group by music type interaction but
no main effect of group or music type (while covarying for differences in sex across groups). Post hoc analysis showed that the
interaction was driven by significant differences between preferred
and neutral music in the MDD + MJ group in voxels localized to
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P = posterior, A = anterior, L = left, R = right. (B) shows the beta weights
associated with each identified cluster that met statistical significance,
separated by music type and by group.

the middle and inferior frontal gyrus, claustrum, putamen, and in
the dorsal ACC. These differences between preferred and neutral
music were specific to this group, and occurred in the absence of
any differences between the groups in subjective music ratings. In
addition, we found a significant positive correlation between individual participant scores of MJ used and fMRI activation during
the preferred music condition in regions localized to the medial
frontal cortex, extending from the medial orbital gyrus (BA 11)
and the ventral anterior ACC (BA 24) to the dorsal ACC (BA 32).
No voxels were identified that showed a significant negative correlation with MJ use. In contrast, we identified a significant negative
correlation between individual participant scores on the BDI and
fMRI activation in the insula, extending into the precentral gyrus
(BA 4) and the postcentral gyrus (BA2). No voxels were identified that showed a significant positive correlation with scores on
the BDI.

September 2014 | Volume 5 | Article 130 | 6

Ford et al.

Neuropathology of marijuana and depression

Table 2 | Peak activations.
Region

k

Peak co-ordinates (MNI)

Degrees of freedom and

x, y, z

T or F -scores

z-Scores

ANCOVA INTERACTION GROUP × MUSIC TYPE
R pre- and postcentral gyrus (BA 4, 3)

934

56, −14, 40

F (3, 113) = 11.95

4.81

L postcentral gyrus (BA 3)

489

−56, −24, 42

F (3, 113) = 11.41

4.69

R middle and inferior frontal gyrus (BA 10, 46)

352

38, 40, 8

F (3, 113) = 10.73

4.53

L cingulate gyrus (BA 32)

277

−6, 6, 44

F (3, 113) = 10.77

4.54

L cingulate and superior frontal gyrus (BA 24, 6)

183

−18, −6, 48

F (3, 113) = 9.65

4.26

4.66

POST HOC MDD + MJ
Preferred > neutral
R middle and inferior frontal gyrus (BA 10, 46)

651

38, 40, 8

T (1, 113) = 4.90

R postcentral gyrus (BA 3)

387

54, −18, 36

T (1, 113) = 4.72

4.50

L pre- and postcentral gyrus (BA 3, 6)

339

−44, −8, 48

T (1, 113) = 4.01

3.87

L cingulate gyrus (BA 24)

375

−6, 4, 46

T (1, 113) = 4.62

4.41

R inferior frontal and precentral gyrus (BA 9, 6)

455

52, 0, 20

T (1, 113) = 4.32

4.14

extending into claustrum and putamen
MULTIPLE REGRESSION
Positive correlation with MJ use
R anterior cingulate (BA 24, 25)

1166

12, 32, 10

T (1, 11) = 5.52

3.74

R hypothalamus

–

6, 0, −18

T (1, 11) = 5.09

3.58

R cingulate and medial orbital gyrus (BA 32,11)

–

8, 24, −12

T (1, 11) = 4.74

3.43

Negative correlation with BDI
R precentral gyrus (BA 4)

790

52, −16, 24

T (1, 11) = 5.74

3.83

R insula (BA 13)

–

38, −8, 16

T (1, 11) = 4.96

3.52

R postcentral gyrus (BA 3)

–

48, −22, 32

T (1, 11) = 4.53

3.33

L, left; R, right; BA, Brodmann area, MNI, Montreal Neurological Institute co-ordinate space; k = number of voxels in a cluster.

The increased BOLD activation identified during the preferred
music condition in the MDD + MJ group suggests a relative hyperactivation in PFC and striatal regions during a non-drug rewarding
stimulus that did not involve decision making or other cognitive processing. These findings were specific to the MDD + MJ
group, and no other group showed this pattern of significantly
increased activation. Frequent cannabis users have been shown
to demonstrate higher fMRI activation to overt cannabis-related
cues in the ventral tegmental area, orbital frontal cortex, ACC, and
striatum (32). Subliminal cannabis cues presented using backward
masking have also been shown to activate reward neurocircuitry
in cannabis-dependent individuals (33). However, debate remains
regarding the processing of natural, non-drug rewards. Our results
suggest similar activation in PFC areas in response to non-drug
rewards in the context of both MDD and MJ use in youth.
Work by Nestor and colleagues (34) have shown that chronic
cannabis users have significantly more right ventral striatum
BOLD activation during non-drug reward anticipation. The
authors suggest chronic cannabis use may modulate reward
processing through sensitizing mesolimbic circuits, creating a
hypersensitivity to other, non-drug rewards. Our results showing increased BOLD activation in the putamen, ACC, and PFC,
all known to be areas involved in reward processing, end support
to this hypothesis. However, it was only when MJ use was combined with MDD in our study that this pattern emerged. This
may be related to the relatively recent onset of drug use in our

www.frontiersin.org

participant group, with an average age of first MJ use between 15
and 16 years, and an average age of 20 years at data acquisition. Any
mesolimbic hypersensitivity that develops with repeated cannabis
exposure may have been more subtle in our participants than in
older, chronic cannabis using populations. Another possibility is
that previous studies may not have accounted for mood symptoms or depression diagnosis in the investigation of MJ users. It
may be that some MJ using participants in prior studies would be
categorized as MDD + MJ if mood were evaluated.
Certainly, a large body of evidence exists suggesting altered
reward-related neurocircuitry in depressed individuals. Abnormalities have been demonstrated in reward-related brain regions
in response to rewarding stimuli in both adults and youth suffering
from depression (14, 15, 35). One study showed a normalization
of hypo-reactivity of reward-related neurocircuitry in rewardbased trials after depressed patients became stably medicated on
an SSRI (36).
Our previous work utilizing a passive music listening task in
MDD showed decreased BOLD activation in MDD patients to
favorite versus neutral music in the nucleus accumbens/ventral
striatum and medial orbital PFC (27). The current results did
not demonstrate this pattern in MDD alone versus HC youth.
One possible reason is that the previous work did not account for
rate of marijuana use. As a result, frequent MJ users who did not
meet criteria for abuse or dependence, which in our experience is
common in youth with mood complaints (37), were not excluded
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FIGURE 2 | ANCOVA post hoc. (A) shows clusters of activated voxels, which
had significantly more activation for preferred compared with neutral music in
the MDD + MJ group in the sagittal, coronal, and transverse perspectives
overlaid on a normalized T1-weighted anatomical image at MNI planes

from the previous study. The results of the current study suggest a relationship between MJ use and MDD that underscores the
importance of accounting for both depression and rate of cannabis
use in studies of functional brain differences in youth.
Of importance, the beta weigh charts illustrate a potentially
interesting pattern. The configuration of the BOLD response to
preferred music in the MDD + MJ group is more similar to the
MDD group than to either the HC or MJ groups in all brain regions
where differences were found, and these differences between preferred and neutral music were larger than in the MDD participants
and often in the opposite direction to the HC and MJ groups’
responses. This suggests that there are unique characteristics in the
combination of MJ and MDD. Two possibilities could be implied
by these results. First, it may be that the use of MJ in the context
of MDD exaggerates abnormal brain modulation found in MDD
alone, perhaps by increased sensitization of mesolimbic circuits,
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indicated. P = posterior, A = anterior, L = left, R = right. No other post hoc
comparisons met statistical correction. (B) shows the beta weights
associated with each identified cluster that met statistical significance,
separated by music type and by group.

creating an increased activation to the preferred music condition.
Or, alternatively, the use of MJ in the context of previous/current
MDD may be an attempt to self-medicate the anhedonia associated with MDD, with a paradoxical “overshoot” of response to
the rewarding stimulus. If MJ has such effects on mesolimbic circuits, it might appeal to individuals who have intrinsic difficulties
with reward processing or negative biases, as is present in MDD.
Regardless of the causal associations, youth with MDD may be
particularly susceptible to the effects of MJ on the brain based
on these findings. It is impossible to tell from the current study
design if this increased perturbation of the mesolimbic system in
the MDD + MJ group would also hold true for youth at risk for
MDD but without current or previous symptoms, posing an interesting question for future research. Further work is required to
determine the mechanism accounting for this interaction between
MJ use and MDD.
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FIGURE 3 | Correlations between MJ use, BDI score, and activation.
(A) Left panel shows voxels with significant positive correlation with MJ
use, overlaid on a normalized T1-weighted anatomical image at MNI
planes of view indicated to clarify localization. P = posterior, A = anterior,
L = left, R = right. (A) Right panel shows a scatter plot indicating the
relationship between individual participant beta weights of the identified
voxels and the number of times they used MJ in the past 28 days. Line

The significant positive correlation we identified between activation in the medial frontal cortex and number of times MJ was
used in the past 28 days in the MJ + MDD group (Figure 3) suggests that brain activation in this region is scaling positively with
this variable, though there could be some “ceiling effect” related
to the number of youth who were smoking 30 or more times (see
scatterplot, Figure 3). These areas comprised multiple regions of
cortex extending from the medial orbital gyrus (BA 11) and ventral anterior ACC (BA 24) to the dorsal ACC (BA 32), and included
the subgenual ACC (BA25) and the hypothalamus. Previous work
investigating non-intoxicated MJ users has described increased
rCBF in the ACC in cannabis users (38), and a correlation between
the total number of smoking episodes per week as well as overall
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of best fit plotted in white. (B) Left panel shows voxels with significant
negative correlation with BDI, overlaid on a normalized T1-weighted
anatomical image at MNI planes of view indicated to clarify localization.
P = posterior, A = anterior, L = left, R = right. (B) Right panel shows a
scatter plot indicating the relationship between individual participant beta
weights of the identified voxels and BDI score. Line of best fit plotted in
white.

cannabinoid level and activation in the cingulate cortex during the
viewing of masked emotional face stimuli (39). In addition, recent
work by Harding and colleagues has shown that increased connectivity between the ACC and a number of areas including the
PFC and anterior insula correlates positively with lifetime exposure to cannabis (40). A number of other studies of cannabis use
have shown task-related fMRI findings of modulation in the ACC,
some showing increases relative to HC (39), and others showing
decreases (41–43). We did not identify activation in the striatum
correlating positively with MJ use, specifically, which would have
been predicted from the incentive salience hypothesis (44), a theory suggesting that repeated exposure to drugs of abuse may lead
to hyperactivity in that region. Again, however, the participants
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studied here were young and in the early stages of cannabis use,
as well as being depression sufferers. There are direct projections
from the subgenual PFC, including BA 25 as found here, to the
ventral striatum, including the nucleus accumbens (45). It may be
that the paradigm we used preferentially activated the PFC rather
than ventral striatal regions, or it could be that the alterations
in ventral striatum develop only after extended years of MJ use.
The positive correlation between BOLD signal and MJ use in the
medial PFC, including the subgenual ACC (BA25) is of particular note given the importance of this region from brain imaging
studies of MDD (46–48), most of which find hyperactivation in
this region. This lends some support to the possibility that the
use of MJ in the MDD + MJ subgroup was associated with greater
abnormality in this critical area of limbic regulation known to be
abnormal in MDD, and reinforces the finding that combined MJ
use with MDD was associated with increased alteration in brain
function in some regions.
In addition, we identified a significant negative correlation
between scores on the BDI and activation in the insula, extending
through the claustrum into the putamen, and in the precentral (BA 4) and postcentral gyri (BA2), as shown in Figure 3B.
This indicated that higher depression scores were associated
with less activation in these brain regions. The critical role of
the insula in depressive symptoms is supported by a body of
evidence including previous work that utilized PET imaging
and principle components analysis of the BDI and found the
psychomotor-anhedonia symptom cluster correlated with lower
absolute metabolism in several areas including the insula, claustrum, and caudate/putamen (49). A large meta-analysis has identified the insula as part of a network of brain regions that are
hypoactive in depressed participants but increase their activation
with treatment (50).
It should be noted that there was a strong correlation between
state anxiety and the BDI in the entire group (Spearman’s r = 0.77,
p < 0.0005) and in the MDD + MJ group alone (Spearman’s
r = 0.79, p = 0.001). So, the negative correlation found here could
be due to anxiety, which is often comorbid with depressed mood.
Overall, our findings have shown relationships between
MJ + MDD and abnormalities in brain regions associated with
emotional processing in response to a natural, non-drug reward
that was not present in either MDD or MJ groups alone, but
which may represent an exacerbation of the negative effects on
brain function of MDD alone and/or an ineffective attempt to
self-medicate abnormal brain function. Future research may help
to clarify this complex relationship. These findings have implications for clinical treatment in that they suggest that the use of
MJ in the context of MDD in young adults imposed additional
brain abnormalities than either alone. In an era when marijuana
products have been suggested by the lay public as a treatment for
depression, these results indicate that controlled clinical trials are
warranted before such an approached should be promoted.
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